Experimental models of Parkinson's disease;Modelos experimentales de enfermedad de Parkinson

Revista de Neurologia

Volumn 31, Issue 1, 2000, Pages 60-66

  Luquin, Ma R ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

1 methy 4 phenyl 1,2,3,6, tetrahydropyridine; 6 hydroxydopamine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROTOXIN; OXIDOPAMINE;

ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; REVIEW; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROTOXINS; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; RATS; SUBSTANTIA NIGRA;

EID: 0034218813     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3101.99654     Document Type: Article

References (64)

1. Luquin MR, Saldise L. Sistema dopaminérgico y muerte neuronal. Rev Neurol 1997; 25: S129-40.
2. Jonsson G, Sachs Ch. Effects of 6-hydroxydopamine on the uptake and storage of noradrenaline in sympathetic adrenergic neurons. Eur J Pharmacol 1970; 9: 141-55.
3. Ungerstedt U. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968; 5: 107-10.
4. Glinka Y, Youdim MHB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol-Environ Toxicol Pharmacol Sect 1995; 295: 329-32.
5. Jonsson G. Studies on the mechanisms of 6-hydroxydopamine cytotoxicity. Med Bil 1976; 54: 406-20.
6. Cadet JL, Katz M, Kackson-Lewis V, Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioural and bichemical evidence. Brain Res 1991; 476: 10-5.
7. Luquin MR, Domínguez JJ, Del Rio L, Zbarsky V, Guillén J. N-acethylcysteine preduces dopaminergic neuronal death induced by 6-OHDA. Mov Disord 1996; 11 (Suppl 1): 144.
8. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB. The iron chelator desferoxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991; 56: 1441-4.
9. Ungersted U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of nigrostriatal dopamine system. Acta Physiol Scand Suppl 1971; 367: 69-93
10. Takeuchi Y, Sawada T, Blunt S, Jenner P, Marsden CD. Effects of 6-OHDA lesions of the nigrostriatal pathway on striatal serotonin innervation in adults rats. Brain Res 1991; 562: 301-5.
11. Taylor MD, De Ceballos ML, Rose S, Jenner P, Marsden CD. Effects of unilateral 6-hydroxydopamine lesion and prolonged 1-3,4-hydroxyphenylalanine treatment on peptidergig systems in the rat basal ganglia. Eur J Pharmacol 1992; 219: 183-92.
12. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 1989; 494: 285-93.
13. Zigmond MJ, Berger TW, Grace AA, Stricker EM. Compensatory responses to nigrostriatal bundle injury: studies with 6-hydroxydopamine in an animal model of parkinsonism. Mol Chem Neuropathol 1989; 10: 185-200.
14. Acheson Al, Zigmond MJ, Stricker EM. Compensatory increase in tyrosine hydroxylase activity in rat brain after intraventricual injection of 6-hydroxydopamine. Science 1980; 207: 537-40.
15. Creese Y, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioural supersensitivity. Science 1977; 197: 596-8.
16. Ichitani Y, Okamura H, Nakahara D, Nagatsu Y, Ibata Y. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injectionin the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra. Exp Neurol 1994; 130: 269-78.
17. Ungersted U, Arbuthnott G. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-93.
18. Hollerman RJ, Grace AA. The effects of dopamine-depleting brain lesions on the electrophyological activity of rat substantia nigra dopamine neurons. Brain Res 1990; 533: 203-12.
19. Lee CS, Sauer H, Björklund A. Dopaminergic neuronal degeneration and motor impairment following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996; 72: 641-53.
20. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastrital terminal lesion with 6-hudroxydopamine a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994; 59: 401-15.
21. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
22. Arai N, Migusi K, Goshima Y, Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 1990; 515: 57-63.
23. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Proc Nat Acad Sci USA 1983; 80: 4546-50.
24. Jenner P, Rupinak NMJ, Rose S, Kelly E, Kilpatrick G, Lees A, et al. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984; 50: 85-90.
25. Johannessen JN, Chiueh CC, Burns RS, Markey SP. Differences in the metabolims of MPTP in the rodent and primate parallel diferences in sensitivity to its neurotoxic effects. Life Sci 1985; 36: 219-24.
26. + binds to neuromelanine. Science 1986; 231: 987-9.
27. Kalaria NR, Harik SI. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissue from mammalian species, including human. J Neurochem 1987; 49: 856-64.
28. Langston JW. Mechanism of MPTP toxicity: more answers more questions. Trends Pharmacol Sci 1985; 6: 375-81.
29. Davis GC, Williams AC, Markey SP, Ebert MH, Calne DE, Richert CM, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogous. Psychiatry Res 1979; 1: 249-51.
30. Elsworth JD, Deutch DE, Redmond Jr JR, Taylor JR, Sladek Jr, Roth RH. Symptomatic and asymptomatic 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience 1989; 33: 323-31.
31. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 1986; 20: 249-55.
32. Forno LS, Langston JW, DeLanney LE, Irwin I. An electron microscopic study of MPTP-induced inclusion bodies an old monkey. Brain Res 1988; 448: 150-7
33. German DC, Dubach M, Askari S, Speciale SG, Bowden DM. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced parkinsonian syndrome in Macaca Fascicularis: which mid-brain dopaminergic neurons are lost? Neuroscience 1988; 24: 161-74
34. Perez-Otaño Y, Herrero MT, Luquin MR, Obeso JA, Del Rio J. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset. Brain Res 1992; 585: 156-60.
35. Perez-Otaño Y, Oset C, Herrero MT, Luquin MR, Obeso JA, Del Rio J. MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci Lett 1994; 175: 121-5.
36. Pifl C, Bertel O, Schingnitz G, Hornykiewicz O. Extrastriatal dopamine in sympomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP). Neurochem Int 1992; (Suppl): 295S-7S.
37. Chiba K, Trevor A, Castaglione Jr N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Bochem Biophys Res Commu 1984; 120: 574-8.
38. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1984; 100: 189-94.
39. Heikkila RE, Manzino L, Cabbat FS, Douvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine by monoamino oxidase inhibitors. Nature 1984; 311: 467-9.
40. Salach JI, Singer TP, Castaglione Jr C, Trevor A. Oxidation of the neurotoxic amine 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) by the monoamino oxidises A and Band suicide inactivation of the enzimes by MPTP. Biochem Biophys Res Commun 1984; 125: 831-5.
41. Konradi C, Kornhuber J, Froelich L, Fritze J, Heinsen H, Beckmann H, et al. Demonstration of monoamino oxidase-A and B in the human brain-stem by histochemical technique. Neuroscience 1989; 33: 383-400.
42. Takada M, Li ZK, Hattori T. Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. Brain Res 1990; 509: 55-61.
43. Di Monte D, Irwin I, Kupsch A, Cooper S, DeLanney LE, Lansgton JW. Diethyldithiocarbamate and disulfram inhibit MPP+ and dopamine uptake by striatal synaptosomes. Eur J Pharmacol 1989; 166: 23-9.
44. Mylitineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion (MPP). J Neurochem 1985; 45: 1951-3.
45. Michel PP, Dandapani BK, Knusel B, Sánchez-Ramps J, Hefti F. Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J Neurochem 1990; 54: 1102-9.
46. Kopin IJ. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Avd Neurol 1986; 45: 137-44.
47. Adams JD, Odunze JN, Sevanian A. Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamine E deficient mice. Biochem Pharmacol 1990; 39: R5
48. Hadjiconstantinou M, Tjioe S, Alho H, Miller C, Neft NH. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) accelerates the accumulation of lipofuscin in mouse adrenal gland. Neurosci Lett 1987; 83: 1-6.
49. Luquin MR, Zbarsky V, Del Rio L, Domínguez JJ, Guilén J. Desferoxamine does not protect against MPP+-induced toxicity in rats. Mov Disord 1996; 11 (Suppl 1): 144.
50. Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreament with diethyldithiocarbamate. Eur J Pharmacol 1985; 119: 127-8.
51. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Mattews RT. Inhibibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996; 2: 965-76.
52. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in the brain: the free radical, nitric oxide. Ann Neurol 1992; 32: 297-311.
53. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985; 36: 2503-8.
54. Ramsay RR, Dagdar J, Trevor A, Singer TP. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 1986; 39: 581-588.
55. Mizuno Y, Sone N, Saitoh T. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-phenyl-pyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem 1987; 48: 1787-93.
56. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S. 1-Methyl-4-phenylpiridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990; 170: 1049-55.
57. Sánchez-Ramos JR, Song, S, Mash DC, Wiener WJ. 21 aminosteroids interact with the dopamine transporter to protect against 1-methyl-4-phenylpyridinium-induced neurotoxicity. J Neurochem 1992; 58: 328-34.
58. Kass GEN, Wright JM, Nicotera P, Orrenius S. The mechanism of I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. Arch Biochem Biophys 1988; 260: 789-97.
59. Turski L, Bressler K, Retting KJ, Löschmann PA, Wachtel H. Protection of substantia nigra neurons from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349: 414-8
60. Kupsch A, Gerlach M, Pupeter SC, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxcity at the nigral but not at striatal level in mice. Neuroreport 1995; 6: 621-5.
61. Xu M, Moratalla R, Gold LH, Hiroi N, Koob GF, Graybiel AM, Tonewaga S. Dopamine D1 receptor mutant mice are deficient in striatal expression of Dynorphin and in dopamine-mediated behavioural responses. Cell 1994; 79: 729-42.
62. Xu M, Hu XT, Cooper EXC, Moratalla R, Graybiel AM, White FJ, et al. Elimination of cocaine-induced mediated neurophysiological effects in dopamine receptor mutant mice. Cell 1994; 79: 945-55.
63. Accili D, Fishbum SC, Drago J, Steiner H, Lachowicz JE, Park BH, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 1996; 93: 1945-9.
64. Baik JH, Picetti R, Salardi A, Thiriet G, Dierich A. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377: 424-8.